EUVIMEDEUVIMED entdecken
Crossref

Seronegative secondary syphilis in a patient treated with ocrelizumab for multiple sclerosis

Ellie Moschkowitz, Inès Chircop, François Durupt, Olivier Harou, Jean Kanitakis, Denis Jullien

European Journal of Dermatology · 2026-02 · 36 (1) · 84-85

DOI: 10.1684/ejd.2026.5040 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Dermatology, 2026-02. Verfasst von Ellie Moschkowitz und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon, France.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BackgroundSystemic antifungals such as terbinafine and itraconazole are often limited by drug interactions and side effects in the treatment of onychomycosis.ObjectivesWe tested a new topical solution to address the clinical need for safer and more effective topical therapies.Materials & MethodsThe solution (containing urea, lactic acid, ethoxydiglycol, decylene glycol, and polyquaternium-7) was applied twice daily for six months in a single-arm, open-label trial, enrolling 50 adult subjects with clinically diagnosed distal lateral subungual onychomycosis. Outcomes included a blinded investigator assessment, mycological evaluation (KOH microscopy and culture), and patient self-assessment of efficacy and usability. Nail growth (mm) was monitored. Complete cure was defined as negative mycological results and resolution of clinical signs. Adverse events were assessed for safety.ResultsForty patients completed the study. At three months, 32/40 of participants (80%) achieved negative mycological results; blinded assessments at this time showed moderate improvement in 24/40 (60%) and excellent improvement in 12/40 (30%) of patients. At six months, the complete cure rate was 50%, (20/40), and 42.5% (17/40) showed significant clinical improvement. Investigators rated the treatment positively in 90.0% (36/40) of cases. Four patients developed mild periungual erythema due to improper application, which spontaneously resolved without discontinuation.ConclusionThis topical “barrier-effect” treatment was associated with improvements in nail appearance and fungal resolution after only 12 weeks, with further benefit at six months, and was safe, well tolerated, and easy to use. Also, concomitant use with systemic antifungals may be possible subject to further studies.

Autor:innen und Institutionen

  • Department of Dermatology, Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon, France.
  • Department of Dermatology, Hospices Civils de Lyon, Croix Rousse Hospital, Lyon, France.
  • Department of Pathology, Lyon Sud Hospital, Hospices Civils de Lyon, Pierre Bénite, France.
  • Department of Dermatology, Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon, France, Department of Pathology, Lyon Sud Hospital, Hospices Civils de Lyon, Pierre Bénite, France.

Zitieren

APA

Moschkowitz, E., Chircop, I., Durupt, F., Harou, O., Kanitakis, J., & Jullien, D. (2026). Seronegative secondary syphilis in a patient treated with ocrelizumab for multiple sclerosis. European Journal of Dermatology, 36(1), 84-85. https://doi.org/10.1684/ejd.2026.5040

Vancouver

Moschkowitz E, Chircop I, Durupt F, Harou O, Kanitakis J, Jullien D. Seronegative secondary syphilis in a patient treated with ocrelizumab for multiple sclerosis. European Journal of Dermatology. 2026;36(1):84-85. doi:10.1684/ejd.2026.5040

BibTeX
@article{Moschkowitz2026,
  author = {Moschkowitz, Ellie and Chircop, Inès and Durupt, François and Harou, Olivier and Kanitakis, Jean and Jullien, Denis},
  title = {Seronegative secondary syphilis in a patient treated with ocrelizumab for multiple sclerosis},
  journal = {European Journal of Dermatology},
  year = {2026},
  volume = {36},
  number = {1},
  pages = {84--85},
  doi = {10.1684/ejd.2026.5040}
}
Kostenlos starten →